In a significant move within the pharmaceutical industry, Novartis has entered into an agreement to launch a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based global biopharmaceutical company renowned for developing innovative medicines in oncology. This acquisition, valued at EUR 2.7 billion, or EUR 68 per share, marks a strategic step for Novartis […]
In a strategic move to bolster its dermatology portfolio, Swiss pharmaceutical giant Novartis has entered into an agreement with MorphoSys and Galapagos to acquire exclusive global development and marketing rights for the atopic dermatitis drug, MOR106. This deal, potentially worth up to $1.1 billion, underscores Novartis’ commitment to advancing care in immuno-dermatology. Under the terms […]
